NICE Rejects AstraZeneca’s Breast Cancer Drug Faslodex

Drug Industry Daily
A A
The UK’s drug cost-effectiveness regulator is rejecting AstraZeneca’s breast cancer drug Faslodex, saying it does not work significantly better than current therapies.

To View This Article:

Login

Subscribe To Drug Industry Daily